Third IPR filed by an investment firm targeting pharma patents
An inter partes review petition has been filed by Ferrum Ferro Capital, challenging a patent owned by Allergan, in a continuation of a trend of hedge funds and financiers targeting large pharmaceutical companies through the Patent Trial & Appeal Board
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: